Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | SVP BUS. AND CORP. DEV. | November 18, 2024 | November 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date November 18, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,981 |
Ending reported balance
After 2024-11-18 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2024-11-18 · Exercise / conversion · Acquired 790 · Balance 57,615 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2024-11-18 · Tax withholding · Disposed 308 · Balance 57,307 F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2024-11-18 · Exercise / conversion · Acquired 2,503 · Balance 59,810 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2024-11-18 · Tax withholding · Disposed 975 · Balance 58,835 F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2024-11-18 · Exercise / conversion · Acquired 1,878 · Balance 60,713 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2024-11-18 · Tax withholding · Disposed 732 · Balance 59,981 F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,693 |
Reported balance
After 2024-11-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-18 · Exercise / conversion · Disposed 790 · Balance 3,693 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,368 |
Reported balance
After 2024-11-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-11-18 · Exercise / conversion · Disposed 2,503 · Balance 23,368 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,048 |
Reported balance
After 2024-11-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-11-18 · Exercise / conversion · Disposed 1,878 · Balance 25,048 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · derivative · entry 9 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,048 Underlying: Common Stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · derivative · entry 8 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,368 Underlying: Common Stock · 2,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · derivative · entry 7 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,693 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 732 | $6.03 | $4,413.96 |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · nonDerivative · entry 6 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,981 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · nonDerivative · entry 5 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 975 | $6.03 | $5,879.25 |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · nonDerivative · entry 4 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,835 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · nonDerivative · entry 3 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $6.03 | $1,857.24 |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,307 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027366 · form4-11202024_111152.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · derivative · entry 9 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,926 Underlying: Common Stock · 1,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · derivative · entry 8 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,871 Underlying: Common Stock · 2,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · derivative · entry 7 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,483 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 732 | $5.53 | $4,047.96 |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · nonDerivative · entry 6 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,825 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · nonDerivative · entry 5 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 975 | $5.53 | $5,391.75 |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · nonDerivative · entry 4 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,679 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · nonDerivative · entry 3 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $5.53 | $1,703.24 |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,151 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 18:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021855 · form4-08212024_100840.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · derivative · entry 9 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,804 Underlying: Common Stock · 1,252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F6 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · derivative · entry 8 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,374 Underlying: Common Stock · 1,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · derivative · entry 7 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,273 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 488 | $5.96 | $2,908.48 |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · nonDerivative · entry 6 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,669 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · nonDerivative · entry 5 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 651 | $5.96 | $3,879.96 |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · nonDerivative · entry 4 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,905 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,669 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · nonDerivative · entry 3 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $5.96 | $1,835.68 |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,887 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 18:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014149 · form4-05222024_100502.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 350 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 18:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007868 · form4-03132024_100332.xml · derivative · entry 3 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,043 Underlying: Common Stock · 3,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 18:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,301 | $7.22 | $9,393.22 |
DisclosureSEC source: 0001415889-24-007868 · form4-03132024_100332.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,055 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 11, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 18:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,338 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-007868 · form4-03132024_100332.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 18:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 30,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007438 · form4-03082024_110327.xml · derivative · entry 2 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,056 Underlying: Common Stock · 30,056 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 18:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 44,736 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007438 · form4-03082024_110327.xml · derivative · entry 1 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,736 Underlying: Common Stock · 44,736 shares Expires 2034-03-06 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:32 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004881 · form4-02222024_100207.xml · derivative · entry 3 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,063 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:32 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $8.38 | $2,581.04 |
DisclosureSEC source: 0001415889-24-004881 · form4-02222024_100207.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,018 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:32 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004881 · form4-02222024_100207.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP BUS. AND CORP. DEV. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 17:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056350 · doc4.xml · derivative · entry 6 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,381 Underlying: Common Stock · 2,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 17:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056350 · doc4.xml · derivative · entry 5 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,853 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 17:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 975 | $5.98 | $5,830.50 |
DisclosureSEC source: 0001209191-23-056350 · doc4.xml · nonDerivative · entry 4 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,536 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 17:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056350 · doc4.xml · nonDerivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 17:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $5.98 | $1,841.84 |
DisclosureSEC source: 0001209191-23-056350 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,008 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 17:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056350 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046827 · doc4.xml · derivative · entry 6 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,884 Underlying: Common Stock · 2,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046827 · doc4.xml · derivative · entry 5 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,643 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 975 | $8.46 | $8,248.50 |
DisclosureSEC source: 0001209191-23-046827 · doc4.xml · nonDerivative · entry 4 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,526 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,503 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046827 · doc4.xml · nonDerivative · entry 3 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 308 | $8.46 | $2,605.68 |
DisclosureSEC source: 0001209191-23-046827 · doc4.xml · nonDerivative · entry 2 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,998 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 21, 2023 20:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046827 · doc4.xml · nonDerivative · entry 1 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 308 share acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| May 18, 2023 Filed May 19, 2023 18:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031246 · doc4.xml · derivative · entry 6 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,387 Underlying: Common Stock · 1,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2023 Filed May 19, 2023 18:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031246 · doc4.xml · derivative · entry 5 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,433 Underlying: Common Stock · 790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2023 Filed May 19, 2023 18:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 651 | $6.69 | $4,355.19 |
DisclosureSEC source: 0001209191-23-031246 · doc4.xml · nonDerivative · entry 4 Poirson Allen · CIK 0001874301 · SVP Bus. and Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,208 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.